Evidence map›Paper›PMID 24555000›Full record

ArticleInternational journal of preventive medicine2014

Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model.

Mitra Navidi-Shishaone, Soheila Mohhebi, Mehdi Nematbakhsh, Shahla Roozbehani, Ardeshir Talebi, Zahra Pezeshki, Fatemeh Eshraghi-Jazi, Safoora Mazaheri, Sohiela Shirdavani, Marjan Gharagozloo and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of preventive medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Animal models of kidney iron overload and ferroptosis: a review of the literature.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Review
  2. Review
  3. Protective effect of silymarin against chemical-induced cardiotoxicity.Iranian journal of basic medical sciences · 2016
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Mitra Navidi-ShishaoneWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Soheila MohhebiWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Mehdi NematbakhshWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Department of Physiology, Isfahan University of Medical Science, Isfahan, Iran ; Isfahan Institute of Basic and Applied Sciences Research, Isfahan, Iran.
Shahla RoozbehaniDepartment of Biology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Ardeshir TalebiWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Zahra PezeshkiWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh Eshraghi-JaziWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Safoora MazaheriWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Sohiela ShirdavaniWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Marjan GharagozlooDepartment of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran.
Behjat Alsaadat MoaeidiDepartment of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRIslamic Azad University of Falavarjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTissue iron deposition may disturb functions of the organs. In many diseases like thalassemia, the patients suffer from iron deposition in kidney and heart tissues. Deferoxamine (DF) is a synthetic iron chelator and silymarin (SM) is an antioxidant and also a candidate for iron chelating. This study was designed to investigate the effect of DF and SM combination against kidney and heart iron deposition in an iron overload rat model.

methodsMale Wistar rats were randomly assigned to 5 groups. The iron overloading was performed by iron dextran 100 mg/kg/day every other day during 2 weeks and in the 3(rd) week, iron dextran was discontinued and the animals were treated daily with combination of SM (200 mg/kg/day, i.p.) and DF (50 mg/kg/day, i.p.) (group 1), SM (group 2), DF (group 3) and saline (group 4). Group 5 received saline during the experiment. Finally, blood samples were obtained and kidney, heart and liver were immediately removed and prepared for histopathological procedures.

resultsThe results indicated no significant difference in kidney function and endothelial function biomarkers between the groups. However, combination of SM and DF did not attenuate the iron deposition in the kidney, liver and heart. DF alone, rather than DF and SM combination, significantly reduced the serum level of malondialdehyde (P < 0.05). Co-administration of SM and DF significantly increased the serum level of ferritin (P < 0.05).

conclusionsDF and SM may be potentially considered as iron chelators. However, combination of these two agents did not provide a protective effect against kidney, liver and heart iron deposition.

Indexed as

Deferoxamineheartiron depositionkidneyliversilymarin

Identifiers

PMID24555000
PMCPMC3915463
OpenAlexW1922733358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.